Mark R. Hutchins, M.D.   I   Daniel F. Moravec, Jr., M.D.   I   Joni A. Tilford, M.D.   I   Madhu V. Midathada, M.D.
 
Non-Hodgkin's Lymphoma

Istodax Active against Refractory Cutaneous T-cell Lymphoma (08/31/2010)
Final results from a Phase II clinical trial provide additional evidence that Istodax® (romidepsin) is active against refractory cutaneous T-cell lymphoma. These results were published in the Journal of Clinical Oncology.

Hepatitis B Virus Linked with Non-Hodgkin’s Lymphoma (08/17/2010)
Individuals with chronic hepatitis B virus (HBV) infection may have an increased risk of developing non-Hodgkin’s lymphoma (NHL), according to findings recently published in The Lancet Oncology.

High Circulating Vitamin D Levels Don’t Reduce Risk of Less Common Cancers (07/12/2010)
High levels of vitamin D in the bloodstream do not appear to reduce the risk of seven less common cancers: endometrial, esophageal, stomach, ovarian, pancreatic, kidney, and non-Hodgkin’s lymphoma.

Maintenance Therapy with Rituxan Prolongs Lymphoma Remission (05/26/2010)
Among patients with follicular lymphoma who responded to initial treatment with chemotherapy and Rituxan® (rituximab), those who received an additional two years of Rituxan as maintenance therapy remained free of lymphoma progression for longer than patients who did not receive maintenance therapy. The results of this Phase III clinical trial will be presented at the 2010 annual meeting of the American Society of Clinical Oncology.

Survivors of Some Childhood Cancers May Face Cognitive Impairment (05/18/2010)
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal of the National Cancer Institute.

Ontak Delays Progression of Patients with Cutaneous T-cell Lymphoma (03/29/2010)
Among patients with cutaneous T-cell lymphoma, treatment with the drug Ontak® (denileukin diftitox) slows disease progression. These results were reported in the Journal of Clinical Oncology.


Latest Non-Hodgkin's Lymphoma by Stage
Aggressive/Intermediate Grade

Survivors of Some Childhood Cancers May Face Cognitive Impairment (05/18/2010)
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal of the National Cancer Institute.

Highly Aggressive/High Grade

Survivors of Some Childhood Cancers May Face Cognitive Impairment (05/18/2010)
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal of the National Cancer Institute.

Indolent/Low Grade

Maintenance Therapy with Rituxan Prolongs Lymphoma Remission (05/26/2010)
Among patients with follicular lymphoma who responded to initial treatment with chemotherapy and Rituxan® (rituximab), those who received an additional two years of Rituxan as maintenance therapy remained free of lymphoma progression for longer than patients who did not receive maintenance therapy. The results of this Phase III clinical trial will be presented at the 2010 annual meeting of the American Society of Clinical Oncology.

Mantle Cell

Survivors of Some Childhood Cancers May Face Cognitive Impairment (05/18/2010)
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal of the National Cancer Institute.

Recurrent

Survivors of Some Childhood Cancers May Face Cognitive Impairment (05/18/2010)
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal of the National Cancer Institute.

Screening/Prevention

Hepatitis B Virus Linked with Non-Hodgkin’s Lymphoma (08/17/2010)
Individuals with chronic hepatitis B virus (HBV) infection may have an increased risk of developing non-Hodgkin’s lymphoma (NHL), according to findings recently published in The Lancet Oncology.

High Circulating Vitamin D Levels Don’t Reduce Risk of Less Common Cancers (07/12/2010)
High levels of vitamin D in the bloodstream do not appear to reduce the risk of seven less common cancers: endometrial, esophageal, stomach, ovarian, pancreatic, kidney, and non-Hodgkin’s lymphoma.

T-Cell

Istodax Active against Refractory Cutaneous T-cell Lymphoma (08/31/2010)
Final results from a Phase II clinical trial provide additional evidence that Istodax® (romidepsin) is active against refractory cutaneous T-cell lymphoma. These results were published in the Journal of Clinical Oncology.

Survivors of Some Childhood Cancers May Face Cognitive Impairment (05/18/2010)
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal of the National Cancer Institute.

4004 Pioneer Woods Dr., Lincoln, NE 68506   I   402.484.4900   I   Toll Free: 877.436.3662